Stay updated on Cladribine, Idarubicin & Cytarabine for AML Clinical Trial
Sign up to get notified when there's something new on the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page.

Latest updates to the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe latest version adds a Study Status entry and Revision: v3.3.3 dated 2025-12-17. The previous HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed on 2025-06-10.SummaryDifference0.5%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedFooter revision label updated to v3.3.2; the previous v3.2.0 label was removed.SummaryDifference0.1%

- Check46 days agoChange DetectedThe notice about government funding and operating status was removed from the page in the latest version. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check67 days agoChange DetectedNew screenshot shows minor UI/layout updates to the header area and the study table presentation on the history page. The underlying content and historical records remain the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check89 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.SummaryDifference11%

- Check96 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release.SummaryDifference0.3%

Stay in the know with updates to Cladribine, Idarubicin & Cytarabine for AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cladribine, Idarubicin & Cytarabine for AML Clinical Trial page.